Rocket Pharmaceuticals, Inc.

RCKT

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001281895

SEC filings (opens in a new tab)

In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 181 institutions reported holding it in 13F filings for Q2 2026, worth $340.9M in total; Maverick Capital is the only superinvestor holding it.

Key figures

Market capClose on Nov 13, 2026: $256.8M
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $426.9K in total: 7
13F holdersQ2 2026, −16 vs. previous quarter: 181
13F valueReported value at the end of Q2 2026: $340.9M
Superinvestors holdingAt the end of Q2 2026: 1

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $0; No comparable prior period
Net income, FY2025: -$223.1M; No comparable prior period
Free cash flow, FY2025: -$190.5M; No comparable prior period
Revenue, Q3 FY2026: $0; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 16.2M; Shares sold short
Change: −39.3K; −0.2% vs. previous
Days to cover: 9.07; At average daily volume

Superinvestors holding RCKT, Q2 2026

Go to the superinvestors tab

1 superinvestor reports holding Rocket Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Maverick Capital

Lee Ainslie

0.1%

Rocket Pharmaceuticals, Inc.'s share of the portfolio

Shares: 3,923,963
Value: $13.4M

Latest insider trades

See all insider trades

Open-market purchases and sales by Rocket Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change
Nov 12, 2026 (view filing)6:44 PM ET	Nov 9	3 days	Chaudhuri SarbaniSee Remarks	SSale	−4.87K	$2.33	−$11.3K	−1.9%257.9K after
Nov 9, 2026 (view filing)4:05 PM ET	Nov 5	4 days	Wilson MartinGeneral Counsel	SSale	−53.4K	$2.39	−$127.8K	−8.9%545.1K after
Sep 15, 2026 (view filing)8:27 PM ET	Sep 11	4 days	Wilson MartinGeneral Counsel	SSale	−75.4K	$3.40	−$256.5K	−11.2%598.5K after
Aug 20, 2026 (view filing)5:30 PM ET	Aug 18	2 days	Wilson MartinGeneral Counsel	SSale	−631	$3.38	−$2.13K	−0.1%673.9K after
Aug 20, 2026 (view filing)5:25 PM ET	Aug 18	2 days	Shah GauravCEO	SSale	−2.29K	$3.38	−$7.75K	−0.2%1.06M after
Aug 17, 2026 (view filing)5:52 PM ET	Aug 13	4 days	Shah GauravCEO	SSale	−2.84K	$3.38	−$9.59K	−0.3%1.06M after
Aug 17, 2026 (view filing)5:50 PM ET	Aug 13	4 days	Wilson MartinGeneral Counsel	SSale	−3.49K	$3.38	−$11.8K	−0.5%674.5K after
Aug 13, 2026 (view filing)4:15 PM ET	Aug 11	2 days	Stevens Christopher JamesChief Operating Officer	SSale	−36.7K	$3.50	−$128.3K	−6.8%505.8K after
Aug 13, 2026 (view filing)4:15 PM ET	Aug 11	2 days	Chaudhuri SarbaniSee Remarks	SSale	−4.70K	$3.50	−$16.4K	−1.8%262.8K after
May 26, 2026 (view filing)	May 21	5 days	Shah GauravCEO	SSale	−55.7K	$3.09	−$172.1K	−5.0%1.06M after

Top 10 13F holders, Q2 2026

See all 181 holders

The largest institutional positions in Rocket Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding RCKT in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
RTW Investments, LP	17,687,772	$60.5M	0.52%	00.0%	Unchanged
BlackRock, Inc.	9,923,962	$33.9M	0.00%	+2,089,167+26.7%	Added
Vanguard Portfolio Management LLC	5,810,033	$19.9M	0.00%	+1,119,818+23.9%	Added
Citigroup Inc	4,865,551	$16.6M	0.01%	−242,157−4.7%	Reduced
Marshall Wace, LLP	4,029,262	$13.8M	0.01%	+990,547+32.6%	Added
Millennium Management LLC	4,000,344	$13.7M	0.01%	+882,220+28.3%	Added
Newtyn Management, LLC	4,000,000	$13.7M	1.71%	+834,100+26.3%	Added
Maverick Capital LtdSuperinvestorMaverick Capital	3,923,963	$13.4M	0.12%	+356,591+10.0%	Added
Vanguard Capital Management LLC	3,784,387	$12.9M	0.00%	+8,651+0.2%	Added
AQR Capital Management LLC	3,386,162	$11.6M	0.00%	+316,232+10.3%	Added